BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
根据最新的财务报表(Form-10K),BNB Plus Corp 的总资产为 $0,净损失为 $0
BNBX 的关键财务比率是什么?
BNB Plus Corp 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
BNB Plus Corp 的收入按细分市场或地理位置如何划分?
BNB Plus Corp 最大收入来源是 Deoxyribonucleic Acid Tagging and Security Products,在最近的收益报告中收入为 1,148,817。就地区而言, Asia and Other 是 BNB Plus Corp 的主要市场,收入为 1,020,556。